An endothelin-converting enzyme mediates the conversion from low-potency pro-endothelin to potent endothelin-1 (ET-1). Increased ET-1 levels have been observed in pulmonary hypertension of various etiologies in infants. We hypothesized that increased ET-1 levels induce pulmonary hypertension during group B Streptococcus (GBS) infusion, and this can be attenuated by the administration of an endothelin-converting enzyme inhibitor (ECEI). Twenty-two unanesthetized, chronically instrumented newborn piglets received a continuous infusion of GBS (3.5 ϫ 10 8 colony-forming units/kg/min) while exposed to 100% O 2 . They were randomly assigned to receive a placebo (PL) or an ECEI (phosphoramidon, 30 mg/kg i.v.) 15 min after sustained pulmonary hypertension. Comparison of hemodynamic measurements and arterial blood gases at baseline and over the first 210 min from the onset of pulmonary hypertension was performed between groups. GBS infusion caused significant increases in mean pulmonary artery pressure, pulmonary vascular resistance (PVR), systemic vascular resistance (SVR), and PVR/SVR, and significant decreases in cardiac output, pH, and base excess. After the administration of ECEI, a significant reduction in pulmonary artery pressure (p Ͻ 0.0001), PVR (p Ͻ 0.001), and PVR/SVR (p Ͻ 0.01) and an improvement in cardiac output (p Ͻ 0.01) were observed during GBS infusion. The decrease in pH (p Ͻ 0.001) and base excess (p Ͻ 0.001) during GBS infusion was less marked after the administration of ECEI compared with the PL. Plasma ET-1 levels were obtained in 20 additional piglets; levels were significantly lower in the ECEI compared with PL after 3 h of GBS infusion (p Ͻ 0.02). All animals in the ECEI group survived the study period as opposed to 25% survival in the PL group (p Ͻ 0.001). These data suggest that the increased circulating ET-1 levels mediate, in part, the GBSinduced pulmonary hypertension. Abbreviations BE, base excess ECE, endothelin-converting enzyme ECEI, endothelin-converting enzyme inhibitor ET-1, endothelin-1 GBS, group B Streptococcus PL, placebo Ppa, pulmonary artery pressure Psa, systemic pressure Pra, right atrial pressure Pwp, pulmonary wedge pressure CO, cardiac output PVR, pulmonary vascular resistance SVR, systemic vascular resistance ABG, arterial blood gas CPB, cardiopulmonary bypass Persistent pulmonary hypertension of the newborn is a clinical syndrome that can occur idiopathically or in association with diverse neonatal cardiorespiratory disorders, such as asphyxia, meconium aspiration, sepsis, pneumonia, acute respiratory distress syndrome, and lung hypoplasia (1). Although striking differences exist among these conditions, they can share common pathophysiologic features, including high pulmonary vascular resistance leading to extrapulmonary right-toleft shunting of blood across the ductus arteriosus or foramen ovale and hypoxemia (2). The incidence is 1.9 in every 1,000 live births (1, 2) and it causes significant morbidity and mortality.
Persistent pulmonary hypertension of the newborn is a clinical syndrome that can occur idiopathically or in association with diverse neonatal cardiorespiratory disorders, such as asphyxia, meconium aspiration, sepsis, pneumonia, acute respiratory distress syndrome, and lung hypoplasia (1) . Although striking differences exist among these conditions, they can share common pathophysiologic features, including high pulmonary vascular resistance leading to extrapulmonary right-toleft shunting of blood across the ductus arteriosus or foramen ovale and hypoxemia (2) . The incidence is 1.9 in every 1,000 live births (1, 2) and it causes significant morbidity and mortality.
The mechanisms that cause severe pulmonary hypertension after birth are characterized by active vasoconstriction, vascular smooth muscle hypertrophy, decreased vascular development, or combinations of the above (2) . The endothelium has been established as a central player by releasing opposing mediators of vascular tone. In pathologic states, the predominant release of vasoconstrictors (thromboxanes, leukotrienes, and endothelin) over vasodilators (nitric oxide and prostacyclin) promotes increased vascular tone and subsequent hypertension. Among the known vasoconstrictors, ET-1 is the most potent (1, 3, 4) . In infants with persistent pulmonary hypertension of varied etiologies, elevated ET-1 levels were demonstrated, and it had a positive correlation with disease severity (4) . ET-1 acts through two membrane receptor proteins, ET A and ET B . ET A mediates vasoconstriction. There are two ET B receptor subtypes: ET B1 , which is located on endothelial cells, mediates vasodilatation through the nitric oxide and prostacyclin pathways, and ET B2 , which is located on vascular smooth muscle cells, mediates vasoconstriction (5) . Various studies in different animal models of pulmonary hypertension have demonstrated that nonselective and selective ET receptor blockade results in attenuation of pulmonary hypertension. However, this amelioration in the pulmonary hypertension was accompanied by a significant decrease in systemic arterial pressure (3, 6, 7) .
Because ET-1 is produced from a two-step cleavage process and ECE is known to catalyze the cleavage of less potent big ET to potent ET-1, ECE inhibition is a plausible treatment alternative. A study using phosphoramidon, an ECE inhibitor, in a CPB pig model, showed attenuation of pulmonary hypertension without affecting the systemic arterial blood pressure (8) .
Elevated ET-1 levels were reported in various studies in adult and neonatal animal models of Gram-negative and -positive sepsis (9 -11) . In the neonatal period, however, the most significant pathogen that causes early-onset fulminant sepsis and pulmonary hypertension is the Gram-positive cocci GBS (12) . GBS produces significant sustained elevation of pulmonary artery pressure and marked decrease in cardiac output and partial pressure of arterial oxygen (PaO 2 ), followed by metabolic acidosis in newborn piglets (13) . We, therefore, hypothesized that increased ET-1 levels induce the pulmonary hypertension observed during GBS infusion in newborn piglets and this can be attenuated by the administration of an ECEI. Our objective was to determine the role of ET-1 on GBS-induced pulmonary hypertension by blocking the production of ET-1 with the ECEI phosphoramidon.
MATERIALS AND METHODS

Animals.
Twenty-two newborn Yorkshire piglets were obtained from a local farmer. They were randomly assigned to the PL or to the ECEI group. The procedures used in their care and handling were in accordance with the guidelines of the National Institutes of Health and the study protocol was reviewed and approved by the Animal Care and Use Committee of the University of Miami.
Animal instrumentation and hemodynamic and blood gas measurements. Anesthesia induction and maintenance was obtained using isoflurane at 1-2% in O 2 at 2-3 L/min via a mask and then a 3.5F endotracheal tube (Mallinckrodt, St. Louis, MO, U.S.A.) for the duration of the surgery. The femoral artery was cannulated with a 5F double-lumen catheter (Umbili-cath, UT Medical Products, West Midvale, UT, U.S.A.) and used for Psa monitoring, bacterial infusion, and blood sampling. The femoral vein was cannulated with a 5F Swan-Ganz thermodilution catheter (Edwards Life Science, Irvine, CA, U.S.A.) advanced to a pulmonary artery branch under fluoroscopic guidance and used for Ppa and Pwp, right Pra, and CO measurements. The catheters were tunneled to the piglet's dorsum, secured in a s.c. pocket, and flushed daily with heparinized saline.
Ppa, Psa, Pra, and Pwp were measured with the use of pressure transducers (Model P23, Gould, Cleveland, OH, U.S.A.) and recorded on a multichannel recorder (Model 2800, Gould). CO was measured by thermodilution technique using a cardiac output computer (Model 9510-A, Edwards Laboratories, Santa Ana, CA, U.S.A.). ABG were determined by using a blood gas analyzer (Model 238, Ciba-Corning, Essex, England) and corrected for core temperature. PVR was calculated as (Ppa Ϫ Pwp)/(CO/kg) and systemic vascular resistance as (Psa Ϫ Pra)/(CO/kg).
Bacterial preparation. Group B ␤-hemolytic streptococci type I a/c isolated from an infected neonate were cultured in Todd-Hewitt broth for 18 h at 37°C. The organisms were collected by centrifugation, washed, and resuspended in sterile Ringer's lactate solution with 5% dextrose at a concentration determined by OD measurements to be equivalent to 1.67 ϫ 10 10 colony forming units (cfu)/mL. The bacterial cell suspension was free of endotoxin as determined by a Limulus amebocyte lysate test (Associates of Cape Cod, Falmouth, MA, U.S.A.), which had a sensitivity of Ͼ0.03 EU/mL. Drug preparation. Phosphoramidon (Peptides International, Louisville, KY) at a dose of 30 mg/kg was dissolved in 5 mL sterile water immediately before drug administration. This dose was selected based on the attenuation of pulmonary hypertension in young pigs under CPB (8) .
Pulmonary hypertension protocol. Forty-eight to seventytwo hours following the surgery, the piglets were placed in an animal sling in a thermoneutral environment and exposed continuously to 100% O 2 via face mask. The piglets showed no signs of discomfort or agitation throughout the study period. After a stabilization period, baseline hemodynamic measurements (Ppa, Pwp, Pra, Psa, and CO) and ABG were obtained. GBS was then continuously infused into the femoral artery catheter at 3.6 ϫ 10 8 cfu/kg/min. Fifteen minutes after sustained pulmonary hypertension, all measurements were repeated. The animals were then given a bolus dose of 5 mL normal saline as PL or phosphoramidon as ECEI according to the group they were assigned to. All the measurements were repeated 15 min after and then every 30 min thereafter, until death or study termination at 4 h. At study conclusion, all animals were killed with an overdose of pentobarbital sodium.
Plasma ET-1 immunoassay. To ascertain the mechanism of action of phosphoramidon in this model, arterial plasma ET-1 levels were measured. Blood samples were collected at baseline before GBS infusion and after 3 h of GBS infusion in both PL (n ϭ 10) and ECEI (n ϭ 10) groups. Samples were centrifuged at 1,000 ϫ g at 4°C for 10 min and the plasma was frozen at Ϫ70°C until assayed by ELISA (Parameter, R & D Systems, Minneapolis, MN, U.S.A.). The plasma purification and assay were done following kit instructions.
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Statistical analysis. Data were analyzed using repeated measures ANOVA and analysis of covariance (ANCOVA) to compare the pattern of response between the ECEI and the PL groups, both over time (time-treatment interaction) and independent of time (overall group difference) for the dependent variables. ANCOVA was used for the comparison of PVR, SVR, and PaO 2 between groups. The 15 min post-GBS measurement was the covariate. Dependent variables included Ppa, Psa, CO, PVR, SVR, PVR/SVR, and ABG. Values used in the analysis included the time from bacterial infusion through 210 min. Significant mortality in the PL group prevented the analysis of data after this time period. Only data from 17 piglets were presented for PVR and PVR/SVR because of technical problems with displacement of the Swan-Ganz catheters in five of the animals. Survival data were analyzed using the MannWhitney test. Data were presented as mean Ϯ SD, and a p value Ͻ0.05 was considered significant. Baseline hemodynamic measurements before bacteria and 15 min after bacterial infusion were comparable between groups. Figure 1A shows the changes in mean pulmonary artery pressure. Ppa increased Ͼ2.5 fold 15 min after GBS infusion in both groups (PL from 14.3 Ϯ 2.3 to 37.0 Ϯ 4.0 mm Hg and ECEI from 13.4 Ϯ 2.7 to 39.6 Ϯ 5.7 mm Hg). In the ECEI animals, there was a significant progressive attenuation in Ppa to 26.1 Ϯ 5.9 mm Hg at 210 min (time-treatment interaction, p Ͻ 0.0001), whereas in the PL animals, the Ppa remained elevated for the duration of the study. PVR increased soon after GBS infusion in both groups. In the ECEI group, PVR decreased after the ECEI was administered and reached a nadir around 90 min, where it was sustained for the duration of the study. In the PL group, the PVR remained elevated until 2 h and progressively increased until study termination (timetreatment interaction, p Ͻ 0.001) (Fig. 1B) . Figure 2A shows the mean Psa. During GBS infusion, Psa slowly decreased over time in both groups and there was no significant difference between groups. The SVR, on the other hand, increased with bacterial infusion in both groups (15-min values were not significantly different between groups). In the ECEI group, the SVR gradually decreased and was maintained around baseline levels, whereas in the PL group, the decrease in SVR was not sustained because of the early mortality. There was, however, no significant difference between groups (Fig.  2B) .
RESULTS
Ten
To compare the relative effects of ECEI on the pulmonary and systemic vasculature, PVR/SVR was calculated. A similar increase in PVR/SVR was seen during GBS infusion in both groups. Whereas in the PL group the PVR/SVR continued to increase over time, in the ECEI group there was a significant sustained decrease in PVR/SVR after ECEI administration (p Ͻ 0.01) (Fig. 3) .
CO decreased markedly with the onset of GBS-induced pulmonary hypertension in both groups. In the ECEI group, the CO increased significantly soon after the ECEI administration and was sustained for the duration of the study. In the PL group, the decrease in CO was maintained for 2 h and further deteriorated for the rest of the study period (time-treatment interaction, p Ͻ 0.01). [ Fig. 4 ]
As seen in Table 1 , pH and BE decreased significantly 15 min after GBS infusion in both groups. However, a more pronounced decrease in the pH (p Ͻ 0.001) and BE (p Ͻ 0.001) over time was observed in the PL group compared with the ECEI animals. The changes in PaCO 2 , PaO 2 , Pwp, Pra, heart rate, and stroke volume during GBS infusion were not different between groups.
Plasma ET-1 levels were similar in both the PL and ECEI groups at baseline before GBS infusion (7. 6 Ϯ 2.8 pg/mL versus 8.2 Ϯ 1.5 pg/mL). After 3 h of GBS infusion, there was an elevation in the plasma ET-1 levels in both groups, however, this was significantly lower in the phosphoramidontreated animals compared with the PL group (32.6 Ϯ 13.8 pg/mL versus 63.6 Ϯ 30.8 pg/mL, p Ͻ 0.02). 
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In the PL group, only 25% of the animals survived the 4-h study period, whereas all animals survived in the ECEI group (p Ͻ 0.001) (Fig. 5) .
DISCUSSION
The present study showed that ET-1 is one of the mediators of the pulmonary hypertension induced by GBS infusion in the newborn piglet. The blockade of ECE with phosphoramidon was associated with decreased ET-1 levels, attenuation of pulmonary hypertension, improved CO, better acid-base status, and prolongation of the survival time during GBS infusion in the unanesthetized newborn piglet.
As blockade of ECE inhibits the conversion of big ET to the potent pulmonary vasoconstrictor ET-1, and consequently decreases the production of ET-1, this may have attenuated the pulmonary hypertension during GBS infusion. During pulmonary hypertension of various causes (4, 9), ET-1 levels have been demonstrated to be elevated. Disease severity correlated with the degree of ET-1 elevation and recovery from the illness occurred when ET-1 levels decreased. To the best of our knowledge, there are no published studies demonstrating the relationship between GBS-induced pulmonary hypertension and ET-1 levels. However, in a model of sterile meningitis induced by GBS injection into the cerebral lateral ventricle, this was associated with elevated levels of cerebrovascular ET-1 and or big ET-1 (14) . Evidence also suggests that ET-1 is an important component of the inflammatory response to sepsis (15) . ET-1 induces the production of cytokines such as tumor necrosis factor-␣, IL-1␣, and IL-1␤. Furthermore, endotoxin, thromboxane, and interleukins among other mediators of inflammation have been described to stimulate the release of ET-1 (15) . This may partially explain the observed elevation of ET-1 in this model of GBS-induced pulmonary hypertension. Values (mean Ϯ SD) for PVR/SVR during hyperoxia and GBS infusion before and after PL or ECEI administration. There was a significant decrease in PVR/SVR in the ECEI group, whereas in the PL group it continued to elevate further.
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Endothelial breakdown (15, 16) , pressure (17) , and hypoxia (18) are the other putative reasons. To eliminate any possible effect of hypoxemia on increasing ET-1 levels and on enhancing pulmonary vasoconstriction (7), the piglets were exposed to 100% O 2 throughout the study period.
Phosphoramidon, though a combined neutral endopeptidase (NEP)/ECE inhibitor, has been shown to decrease ET levels in cultured cell in vitro (19) . It inhibits neutral endopeptidase 24.11 and other metalloproteases. Neutral endopeptidase 24.11 is an enzyme that normally catalyzes the degradation of angiotensin II, III, and I, bradykinin, and oxytocin (8, 20) . In an in vivo model, phosphoramidon administered to young piglets before CPB decreased the magnitude of post-CPB pulmonary hypertension, indication that the administration of phosphoramidon attenuated pulmonary hypertension by decreasing the production of ET-1 (8) . Also, because it has been demonstrated that pulmonary artery smooth cells exposed to ET-1 had an increased production of superoxide (21), and the latter has been associated with pulmonary vasoconstriction (22) , then inhibition by phosphoramidon may decrease superoxide release. This effect may not be significant inasmuch as administration of superoxide dismutase did not attenuate GBS-induced pulmonary hypertension in the lamb (23) . Additionally, during sepsis, there may be increased release of nitric oxide systemically (24, 25) , which can result in increased peroxynitrite levels. Peroxynitrite has been shown to inhibit endothelial nitric oxide synthase (eNOS) activity, although the mechanism is unknown (21) . Administration of phosphoramidon could therefore potentially decrease peroxynitrite generation and improve eNOS activity, and even further attenuate pulmonary hypertension.
A significant decline in arterial blood pressure was observed after GBS infusion in both groups. Different animal models using GBS showed varied effects on the systemic blood pressure, with greater tendency toward producing hypotension, especially during the later phase of the infection (13) . It has been demonstrated that several mechanisms could contribute to this. First, sepsis and ET-1 stimulate the release of proinflammatory cytokines such as tumor necrosis factor-␣, platelet activating factor, and IL (15, 26) . The participation of these cytokines in the systemic inflammatory response syndrome and cardiovascular failure has been established and is described to contribute to the observed systemic hypotension (9, 15) . Second, sepsis induces nitric oxide synthase (iNOS) in the endothelial and vascular smooth muscle cells, enhancing vasodilatation especially during the late phase of sepsis (24, 25) . Moreover, Markewitz et al. (27) demonstrated that ET-1 decreased iNOS mRNA in cytokine-stimulated rat epithelial cells and this effect was reversed by phosphoramidon. The use of phosphoramidon as a nonselective NEP/ECE inhibitor might also affect or decrease degradation of atrial natriuretic peptide, an endogenous vasoactive peptide that induces vasodilatation. NEP inhibition has been previously associated with increased Mean Ϯ SD. * p Ͻ 0.05 (PL vs ECEI).
Figure 5.
Percentage survival over time. All animals in the ECEI group survived the study period, whereas the PL group animals showed a significantly lower survival rate.
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levels of atrial natriuretic peptide in the circulation (20) and, thereby, the net increase of vasodilators and systemic hypotension. This possible effect does not explain the similar reduction in Psa during GBS infusion between the PL and ECEI groups. In addition, the significant decrease in PVR/SVR over time observed after ECE inhibition suggests that phosphoramidon has a more predominant effect in the pulmonary than the systemic vasculature. GBS in neonates is known to decrease cardiac output or produce "cold" shock (28) . This was duplicated in the study, and it improved with ECE inhibition. This effect presumably is because of the decrease in ET-1 production, especially because ET-1 promotes coronary vasoconstriction through the ET A receptors (9, 29) . Also, elevated thromboxane levels have been associated with the reduction in CO seen during GBS sepsis (30) . Because ET-1 has been shown to potentiate the release of thromboxane, inhibition by phosphoramidon would be expected to decrease thromboxane release and thereby further improve cardiac output. Another explanation could be the afterload reduction, as seen in this study and in experiments with congestive heart failure and administration of ET A receptor antagonists (7, 31) . Because ET-1 also produces negative inotropy (7), decreasing its production can improve CO.
The development of metabolic acidosis during GBS sepsis has been attributed to progressive tissue ischemia resulting from reduced oxygen delivery (28, 32, 33) . In the ECEI group, as a consequence of improvement in CO, systemic O 2 delivery is preserved, improving O 2 utilization as reflected by a lesser degree of metabolic acidosis. Also, local tissue ischemia associated with the increased cytokine release (34) would be further lessened by phosphoramidon. This may have contributed to the improved survival during the study period.
In conclusion, the pulmonary hypertension observed during GBS infusion in newborn piglets is associated with elevation of plasma ET-1 levels and this was attenuated by the administration of an ECE inhibitor. This suggests that the pulmonary vasoconstriction is, in part, mediated by an increase in circulating levels of ET-1. The effect of the ECE inhibitor phosphoramidon was predominant in the pulmonary vasculature, because the PVR/SVR decreased significantly in the treated newborn piglets.
